An injectable drug that makes fat cells die on command, rather than merely shrinking them, has now shown in human testing that it can reduce visceral fat — the metabolically dangerous fat that wraps around the liver, pancreas, and intestines — not just the fat you can pinch under the skin.
Key Points
- CBL-514, an injectable developed by Taiwan-based Caliway Biopharmaceuticals, produced a 12.01% average reduction in visceral-fat volume on MRI, against a 5.68% increase in the placebo group, in reported Phase 2 trial data.
- The drug works by triggering apoptosis — programmed cell death — directly in fat cells at the injection site, a mechanism distinct from appetite-suppressing GLP-1 drugs like semaglutide and tirzepatide.
- A peer-reviewed Phase 2 publication already confirms CBL-514’s primary, better-documented effect: a statistically significant reduction in abdominal subcutaneous fat (P <.001).
- The trials enrolled dozens to just over 100 participants and tracked outcomes for only weeks after the final injection, placing this squarely in early-stage evidence.
- Visceral fat is independently linked to insulin resistance and metabolic disease, which is why an injectable that targets it — rather than subcutaneous fat alone — has drawn serious clinical interest.
What the Trial Actually Measured
The reported results come from two Phase 2 studies of CBL-514, in which participants received a series of lower-abdominal injections every three weeks for up to twelve weeks, with doses reaching 600 mg. Four weeks after the final treatment, investigators used MRI — not a proxy like waist circumference or body weight — to quantify visceral fat volume directly. The CBL-514 group averaged a 12.01% reduction; the placebo group averaged a 5.68% increase. MRI is the right tool for this question: it distinguishes visceral fat from subcutaneous fat with a precision that scales and tape measures simply cannot match, which is why regulators and researchers treat it as the gold-standard endpoint for this kind of claim.
That said, the strongest and most fully documented evidence on CBL-514 to date concerns a different fat compartment. The peer-reviewed Phase 2 publication, randomizing 76 participants 2:1 to drug versus placebo, reports its primary endpoint as abdominal subcutaneous fat — the fat layer just beneath the skin — with a between-group volume difference of -312.08 mL at four weeks and -276.83 mL at eight weeks, both highly significant statistically. The 12% visceral-fat figure is real and comes from the same clinical program, but it currently lives in secondary reporting rather than in a dedicated peer-reviewed paper with its own disclosed sample size and confidence interval. Readers should hold both facts at once: subcutaneous-fat reduction is the well-documented result; visceral-fat reduction is the newer and, for now, less fully published one.
The Mechanism: Apoptosis Instead of Appetite Suppression
CBL-514 belongs to a different drug class than the GLP-1 receptor agonists that have reshaped obesity treatment over the past five years. Tirzepatide and semaglutide work upstream, in the brain and gut, dialing down appetite and slowing gastric emptying so patients eat less. CBL-514 works locally: injected directly into fat tissue, it is designed to trigger apoptosis in adipocytes — the fat cells die and are cleared by the body, rather than simply shrinking in size as happens with caloric restriction or exercise. This is conceptually closer to older fat-reduction technologies like cryolipolysis (CoolSculpting) than to a systemic metabolic drug, except that it is delivered by injection rather than external cooling and is being tested specifically for its effect on fat volume measured by imaging, not just cosmetic contour.
The company behind the drug, Caliway Biopharmaceuticals, has run this program through a now-familiar sequence of early-phase studies: a pharmacokinetic study in healthy volunteers, randomized placebo-controlled efficacy trials in the 75-to-107-participant range, and a Phase 2b trial testing the subcutaneous-fat indication more broadly. That sequencing — safety first, then efficacy in progressively larger cohorts — is standard drug development, and CBL-514’s track record through it has been clean enough to advance rather than stall.
Why Visceral Fat Is the Fat That Matters Medically
Not all body fat carries equal risk. Subcutaneous fat, the layer under the skin, is largely a cosmetic and comfort concern. Visceral fat is a different animal: it surrounds internal organs, secretes inflammatory signals directly into the bloodstream, and is tightly linked to insulin resistance, fatty liver, and cardiovascular risk. Large lifestyle-intervention studies have found that a 10% reduction in visceral fat tracks with meaningfully better long-term metabolic-risk scores, and some analyses have tied visceral-fat loss to roughly a 28% lower risk of developing type 2 diabetes over time. That context is what makes a 12% reduction from an injectable worth taking seriously — if it holds up, replicates, and proves durable, it would sit in the same ballpark of biological significance as reductions currently achieved through intensive diet and exercise programs, or through GLP-1 therapy, but via an entirely different route.
NEW TREATMENT: An experimental injection called CBL-514 slashed dangerous visceral fat — the deep abdominal fat wrapped around internal organs — by 12% in early human trials, while patients on a placebo saw their visceral fat increase nearly 6%.
The drug works by selectively… pic.twitter.com/23PMe6LG62
— Fox News Health (@foxnewshealth) October 12, 2026
What Comes Next
These results come from Phase 2 trials, the stage that precedes the larger, longer Phase 3 studies regulators require before approval — a normal and expected position for a drug at this point in development, not a mark against it. The open questions that matter most are practical: whether the visceral-fat reduction persists beyond the four-week measurement window, whether it translates into measurable improvements in insulin sensitivity or other metabolic markers, and whether it reproduces at scale in a dedicated, fully reported visceral-fat trial. CBL-514 is also being studied in combination with GLP-1 drugs in animal models, where early data suggest it may reduce the weight regain that often follows discontinuation of appetite-suppressing medication — a problem that has become one of the central practical limitations of the GLP-1 era. If that combination effect holds in humans, CBL-514’s more durable contribution to metabolic medicine may ultimately be as a partner therapy rather than a standalone treatment.
Sources:
foxnews.com, clinicaltrials.gov, pmc.ncbi.nlm.nih.gov, academic.oup.com, cdn.clinicaltrials.gov, clareohealth.com
